These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 26829386)

  • 1. Effect of ipragliflozin, an SGLT2 inhibitor, on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats.
    Takakura S; Toyoshi T; Hayashizaki Y; Takasu T
    Life Sci; 2016 Feb; 147():125-31. PubMed ID: 26829386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of hyperglycemia on diabetic complications in obese type 2 diabetic SDT fatty rats: effects of SGLT inhibitor phlorizin.
    Katsuda Y; Sasase T; Tadaki H; Mera Y; Motohashi Y; Kemmochi Y; Toyoda K; Kakimoto K; Kume S; Ohta T
    Exp Anim; 2015; 64(2):161-9. PubMed ID: 25736710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute and Direct Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glomerular Filtration Rate in Spontaneously Diabetic Torii Fatty Rats.
    Takakura S; Takasu T
    Biol Pharm Bull; 2019; 42(10):1707-1712. PubMed ID: 31582658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-dose effect of the SGLT2 inhibitor ipragliflozin on cardiovascular activity in spontaneously diabetic Torii fatty rats.
    Takakura S; Takasu T
    Clin Exp Pharmacol Physiol; 2019 Mar; 46(3):266-273. PubMed ID: 30485488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats.
    Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
    J Pharm Pharmacol; 2014 Jul; 66(7):975-87. PubMed ID: 24533859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of ipragliflozin, an SGLT2 inhibitor, on cardiac histopathological changes in a non-diabetic rat model of cardiomyopathy.
    Takasu T; Takakura S
    Life Sci; 2019 Aug; 230():19-27. PubMed ID: 31125563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto-Kakizaki Rats.
    Takasu T; Hayashizaki Y; Hirosumi J; Minoura H; Amino N; Kurosaki E; Takakura S
    Biol Pharm Bull; 2017; 40(5):675-680. PubMed ID: 28458353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antidiabetic effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed diets containing different carbohydrate contents.
    Tahara A; Takasu T
    Life Sci; 2018 Mar; 197():80-90. PubMed ID: 29425766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo.
    Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Qun L; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
    Naunyn Schmiedebergs Arch Pharmacol; 2012 Apr; 385(4):423-36. PubMed ID: 22139434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice.
    Tahara A; Takasu T
    Eur J Pharmacol; 2018 Jul; 830():68-75. PubMed ID: 29702076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.
    Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
    Eur J Pharmacol; 2013 Sep; 715(1-3):246-55. PubMed ID: 23707905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the SGLT2 inhibitor ipragliflozin on various diabetic symptoms and progression of overt nephropathy in type 2 diabetic mice.
    Tahara A; Takasu T
    Naunyn Schmiedebergs Arch Pharmacol; 2018 Apr; 391(4):395-406. PubMed ID: 29374293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the SGLT2 inhibitor ipragliflozin on food intake, appetite-regulating hormones, and arteriovenous differences in postprandial glucose levels in type 2 diabetic rats.
    Tahara A; Kondo Y; Takasu T; Tomiyama H
    Biomed Pharmacother; 2018 Sep; 105():1033-1041. PubMed ID: 30021338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glomerular hyperfiltration with hyperglycemia in the spontaneously diabetic Torii (SDT) fatty rat, an obese type 2 diabetic model.
    Sano R; Ishii Y; Yamanaka M; Yasui Y; Kemmochi Y; Kuroki F; Sugimoto M; Fukuda S; Sasase T; Miyajima K; Nakae D; Ohta T
    Physiol Res; 2021 Mar; 70(1):45-54. PubMed ID: 33453716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Effects of SGLT2 Inhibitor Ipragliflozin and Metformin on NASH in Type 2 Diabetic Mice.
    Tahara A; Takasu T
    Endocr Res; 2020; 45(2):147-161. PubMed ID: 31955626
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice.
    Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
    Arch Pharm Res; 2016 Feb; 39(2):259-270. PubMed ID: 26450351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice.
    Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Qun L; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
    J Pharmacol Sci; 2012; 120(1):36-44. PubMed ID: 22971845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective Effect of Ipragliflozin on Pancreatic Islet Cells in Obese Type 2 Diabetic db/db Mice.
    Takasu T; Takakura S
    Biol Pharm Bull; 2018; 41(5):761-769. PubMed ID: 29709913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats.
    Hayashizaki-Someya Y; Kurosaki E; Takasu T; Mitori H; Yamazaki S; Koide K; Takakura S
    Eur J Pharmacol; 2015 May; 754():19-24. PubMed ID: 25701721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antidiabetic and antiobesity effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed sugar solution.
    Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
    Eur J Pharmacol; 2018 Jan; 818():545-553. PubMed ID: 29154936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.